Navigation Links
Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
Date:4/15/2011

PHILADELPHIA (April 15, 2011) The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2 (NF2), an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have profound implications for NF2 and related cancers, such as mesothelioma.

The researchers describe, for the first time, that Merlin, the protein encoded within the NF2 gene interacts with a protein called angiomotin. This connection between Merlin and angiomotin also brings together two important information networks in cells, both of which have been implicated in numerous forms of cancer. It is a connection, the researchers say, between the sensors that detect interactions between cells and the signaling networks that drive cell division.

"Angiomotin is required for movement of cells that form new blood vessels, so it is fascinating to see it so closely linked to merlin, the product of the NF2 gene, loss of which leads to tumor formation," said Joseph Kissil, Ph.D., senior author of the study and associate professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. "The discovery opens up a potential new method to treat NF2 by attacking the tumor cells directly and by starvation, a strategy already employed in certain cancer therapies."

"Drugs like Avastin, for example, target the growing blood vessels," Kissil said, "but what makes angiomotin a tempting target is that it is used by both blood vessels and the growing tumor cells that need the nutrients these blood vessels provide."

NF2 is a genetic disorder caused by a mutation in both copies of a person's NF2 gene. It occurs in about one in every 30,000 people, and it is mostly hereditary. NF2 generally appears as benign tumors in the nervous system of young adults, often causing deafness as tumo
'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3934
The Wistar Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Wistar researchers discover new class of objects encoded within the genome
2. Wistar scientists explain the persistence of melanoma through dynamic stemness
3. Whales Not Just Singing the Same Old Song, Researchers Say
4. Boston University researchers find most substance-dependent individuals report poor oral health
5. University of Granada researchers make the first bioartificial organ in Spain
6. Queens researchers pioneer needle-free test for premature babies
7. Mechanism for invasion of tumorous cells discovered by Hebrew University researchers
8. Researchers find anatomic differences after robotic-assisted radical prostatectomy
9. Researchers present new findings on cancer and gene therapy
10. Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen
11. Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 Minor fender benders and serious ... require parties to the accident to respond appropriately to ... and Prevention (CDC) data from 2010, accidents, including car ... In fact, in 2005, automobile accident-related deaths ... more than 2.3 million drivers and passengers receive treatment ...
(Date:5/19/2013)... Columbus, OH (PRWEB) May 19, 2013 ... LLC continue to follow developments in the nation’s first ... The case, underway in Washington State Superior Court, was ... several years after he suffered complications in a robot-assisted ... The Da Vinci robotic surgery lawsuit ...
(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
(Date:5/18/2013)... 19, 2013 The American Society for Gastrointestinal Endoscopy ... endoscopy during the ninth annual ASGE Crystal Awards on ... ASGE Foundation, this year,s event will begin at ... Fla. , Held in conjunction with Digestive Disease ... in leadership, research and scientific pursuit. The event will ...
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The American ... announce its 2013 research scholars. This year,s honorees ... in gastroenterology, hepatology or related areas, and with ... , "These young researchers are the future ... young scholars who are paving the way for ...
Breaking Medicine News(10 mins):Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... a specialty,bank consulting firm, has moved its affiliation to ... independent office of,John Hancock Financial Network in Buffalo, NY, ... to the entire network nationally,announced Peter Gordon, President of ... are excited to be able to offer this specialized ...
... In a statewide survey of medical professionals, 38 physician-scientists ... Medical Center (LA BioMed) are honored for being ... issue of Los Angeles magazine. , Key Professional Media, ... professionals to compile the 2008 list of Southern California ...
... of West,Virginia, Inc. and the Nitro Walmart Marketplace are working ... significant,increase for unexpected emergency needs assistance. , ... events, being held this Friday and,Saturday, more than $20,000 in ... food that will help thousands of area families pay bills, ...
... Clinically Proven, Anti-Aging REVALESKIN(R) Skin Care Brand Launches ... and REVALESKIN(R) Chest/Decolletage Rejuvenating Treatment, All Exclusively Formulated ... , CORAL GABLES, ... of the extraordinarily successful introduction of the core ...
... , , NEW YORK, Dec. 4 ... that it has repurchased 640,930 shares of WebMD Class A Common ... LLC, which was acquired by WebMD in December 2006. In ... in cash pursuant to the terms of the previously completed Subimo ...
... Dec. 4 The Perrigo Company,(Nasdaq: PRGO ... Desloratadine tablets (5 mg) has been settled with Perrigo ... been sued for patent infringement of,US Patent Nos. 6100274, ... ANDA,containing a Paragraph IV certification. Under the terms ...
Cached Medicine News:Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 2Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 3Health News:LA BioMed researchers among Southern California Super Doctors 2Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 3Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 4Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 5Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 6Health News:WebMD Announces Repurchase of 640,930 of its Shares 2Health News:Perrigo Settles Desloratadine Patent Litigation 2Health News:Perrigo Settles Desloratadine Patent Litigation 3
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Patients with active moderate to severe rheumatoid arthritis ... or adalimumab (Humira ® ) and who were actively ... from baseline at week 10, and sustained response through ... 26 results from the RESTART study were presented for ...
... LLC, the image analysis and pattern recognition technology provider, ... of $244,479.25 under the U.S. Government,s Affordable Care Act. ... projects that show significant potential to produce new therapies, ... health care costs or advance the goal of curing ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: